Resources
About Us
Home Report
Store
Digital Therapeutics Market
Digital Therapeutics Market Size, Share, Forecast, & Trends Analysis by Application (Mental health, Diabetes, Respiratory, Neurology, Addiction, Rehabilitation, Oncology, Sleep Disorder) Type (Disease Prevention, Management) End User-Global Forecast to 2031
Report ID:MRHC - 104743 Pages: 197 Nov-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursThe Digital Therapeutics Market was valued at $6.46 billion in 2023. This market is expected to reach $56.34 billion by 2031 from an estimated $8.26 billion in 2024, at a CAGR of 31.5% during the forecast period of 2024-2031
Digital Therapeutics Market Size & Forecast
The increasing prevalence of therapeutics, rising focus on preventive healthcare and self-testing, rising investment in digital therapeutics, and increasing internet users are driving the growth of this market. Furthermore, the untapped market in emerging economies and the growing pipeline of digital therapeutics are expected to generate growth opportunities for the stakeholders in this market.
Key Findings
- By Type: The Disease Management and Treatment DTx Segment Dominates the Digital Therapeutics Market in 2024
- By Application: The Mental Health Segment to Dominate the Digital Therapeutics Market in 2024
- By End User: The Providers Segment is Expected to Dominate the Digital Therapeutics Market in 2024
- By Geography: North America to Dominate the Digital Therapeutics Market in 2024
Digital Therapeutics Market Driver
The Rising Prevalence of Chronic Diseases is Driving the Growth of this Market
The global prevalence of chronic diseases and conditions, such as diabetes, arthritis, and heart disease, is steadily rising. According to the WHO, in 2020, chronic diseases affected an estimated 57% of the global population, and each year, 41 million people die from these conditions, accounting for 71% of all global deaths. The growth of the aging population and changes in social behaviors are major contributors to the increasing number of individuals suffering from chronic diseases. For example, the International Diabetes Federation reported that, in 2019, 19.3% of people aged 65 and above were affected by diabetes. In North America and the Caribbean, the prevalence of diabetes in this age group rose from 26.3% in 2017 to 27.0% in 2019, with projections indicating it will reach 27.3% by 2030. Similarly, in Europe, diabetes prevalence among people aged 65 and above increased from 20.4% in 2017 to 24.2% in 2019, with an expected increase to 24.7% by 2030. As a result, the growing prevalence of chronic diseases is driving the adoption of digital therapeutic solutions for continuous health monitoring and management.
The global population aged 65 years or older is projected to more than double, increasing from 761 million in 2021 to 1.6 billion by 2050 (Source: United Nations). Developing regions such as Asia, Latin America, and Africa are expected to have the highest proportions of individuals aged 65 and above, followed by Europe and North America. The geriatric population is particularly vulnerable to a range of chronic diseases. As a result, the growing aging population, combined with the rising prevalence of chronic conditions, is driving the growth of the digital therapeutics market.
Increasing Focus on Preventive Healthcare and Self-testing is Driving the Market
Preventive care plays a crucial role in preventing illness, enabling early disease diagnosis, and promoting a healthy lifestyle. By focusing on prevention, it reduces the likelihood of disabilities, diseases, and premature death. However, many patients worldwide lack access to preventive care due to factors such as the shortage of primary care providers, high costs, geographical barriers, and limited awareness.
Digital therapeutics support disease prevention by offering clinically validated preventive care interventions. As the focus on preventive healthcare grows, major market players and governments worldwide are ramping up investments, policies, and initiatives to promote this approach. For example, in March 2021, the European Commission launched the EU4Health program for 2021–2027, with an investment of USD 6.03 billion (EUR 5.1 billion) aimed at disease prevention, health promotion, digital transformation of the healthcare system, and the integration of digital services and tools, among other key areas of intervention.
Digital therapeutics, which utilize software solutions and connected devices, are increasingly being adopted for self-testing. The rising focus on self-testing for improved disease management is contributing to the growing adoption of digital therapeutics, thereby driving the market's growth.
Digital Therapeutics Market Opportunities
Untapped Markets in Emerging Economies are an Opportunity for the Digital Therapeutics Market
Emerging economies worldwide are driving the demand for healthcare services and treatments, fueled by rapid urbanization, improvements in healthcare infrastructure, rising healthcare expenditures, increased healthcare insurance coverage, higher disposable incomes, and the growing prevalence of both non-communicable and infectious diseases.
According to the World Bank, the total population of emerging countries is projected to reach approximately 3.4 billion by 2050. Additionally, the International Diabetes Federation reports that the global number of people with diabetes aged 20–79 rose from 425 million in 2017 to 537 million in 2021, with estimates suggesting this number will reach 643 million by 2030. These factors are expected to significantly drive the demand for digital therapeutics in the coming years.
Growing urbanization and rising GDP per capita in emerging economies such as South Africa, India, Brazil, China, Bangladesh, and Thailand are driving the demand for healthcare services and treatments. Urbanization typically correlates with higher wages, an improved quality of life, and better access to healthcare services. As urbanization accelerates in these regions, it is expected to spur the development of healthcare systems, expand access to healthcare, and facilitate the widespread adoption of digital therapeutics in urban areas.
Given the overall scenario, factors such as the increasing prevalence of chronic and infectious diseases, population growth, and rising urbanization are expected to drive the demand for digital therapeutics solutions in emerging countries. This, in turn, is creating substantial growth opportunities for companies operating in the market.
Digital Therapeutics Market Analysis: Top Market Opportunity:
The Disease Management and Treatment DTx Segment is Expected to Dominate the Digital Therapeutics Market in 2024
Based on type, the digital therapeutics market is segmented into disease management and treatment DTx and disease prevention DTx. In 2024, the disease management and treatment DTx segment is expected to account for the largest share of 76.5% of the digital therapeutics market.
The large market share of this segment is driven by the availability of cost-effective digital therapeutics solutions for disease management, the increasing need to reduce healthcare costs due to the rising economic burden of healthcare, and higher investments in digital therapeutics. For example, in December 2021, Limbix Health, Inc. secured USD 15 million in funding to develop mental health solutions for adolescents. Similarly, in May 2021, Noom Inc. (U.S.) raised USD 540 million to expand its behavior-change platform into virtual treatments for conditions such as high blood pressure, diabetes, stress, and sleep disorders.
Additionally, the growing global burden of chronic diseases is driving the demand for digital therapeutics (DTx) solutions for disease management and treatment. Digital therapeutics aim to improve care delivery, enhance patient outcomes, and boost patient engagement and empowerment. By leveraging technology, these solutions have the potential to transform healthcare by optimizing care processes, expanding access to treatment, and fostering patient-centered approaches to care.
Geographical Analysis
North America Dominates the Digital Therapeutics Market in 2024
In 2024, North America is estimated to account for the largest share of 43.6% of the digital therapeutics market.
The large share of the North American digital therapeutics market is driven by several factors, including the increasing prevalence of chronic diseases, a surge in the use of digital health products, and growing awareness among patients about digital therapeutics solutions. Additionally, the region is home to a high number of digital therapeutics companies, such as 2Morrow Inc., Welldoc, Inc., BigHealth, Teladoc Health, Inc., and DarioHealth Corp., all based in the U.S. The U.S. government has also been supportive of digital therapeutics, particularly during the COVID-19 pandemic. For example, in April 2020, the U.S. Food and Drug Administration (FDA) relaxed certain premarket requirements for smartphone apps and programs designed to support the treatment of conditions like anxiety, obsessive-compulsive disorder, insomnia, and depression. These factors have significantly contributed to North America's dominant position in the digital therapeutics market.
However, Asia-Pacific is slated to register the highest CAGR of 34.1% during the forecast period. The growth of digital health infrastructure in the APAC region is being driven by several factors, including a shortage of healthcare professionals, the need to reduce healthcare costs, the increasing prevalence of chronic diseases, and the growing consumer preference for mobile applications to manage digital health. These factors are collectively fueling the growth of the digital health market in the region.
Key Companies
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past years (2021–2024). The key players operating in the global digital therapeutics market are Noom, Inc. (U.S.), 2Morrow Inc. (U.S.), GAIA AG (Germany), ResMed Inc. (U.S.), Canary Health (U.S.), Welldoc, Inc. (U.S.), DarioHealth Corp. (U.S.), Akili, Inc. (U.S.), Biofourmis Inc. (U.S.), Big Health (U.S.), Teladoc Health, Inc. (U.S.), Limbix Health, Inc. (U.S.), Kaia Health Software Inc. (Germany), Glooko, Inc. (U.S.), and Virta Health Corp. (U.S.).
Digital Therapeutics Industry Overview: Latest Developments from Key Industry Players
- In June 2024, Teijin Pharma Limited (Japan) and CureApp, Inc. (U.S.) signed a joint marketing and sales agreement for the Prescription Digital Therapeutic App for Hypertension. Through the partnership, the companies aim to expand the use of CureApp HT, which supports lifestyle modifications for hypertension treatment.
- In May 2024, Otsuka Pharmaceutical Co., Ltd. (Japan) launched a subsidiary, Otsuka Precision Health, to commercialize its digital therapeutic Rejoyn and other digital therapeutics and connected health products.
- In April 2024, Otsuka Pharmaceutical Co., Ltd. (Japan) and Therapeutics, Inc. (U.S.) jointly developed the mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder.
- In January 2024, Big Health (U.S.) raised USD 75 million in a series C funding round to accelerate the company’s commercial reimbursement model and product platform, including six new digital therapeutics by 2024. The funding was provided by SoftBank Vision Fund (U.S.), with participation from ArrowMark Partners (U.S.) and existing investors Octopus Ventures (U.K.), Gilde Healthcare (Netherlands), Kaiser Permanente Ventures (KPV) (U.S.), and Morningside Ventures (U.S.).
- In January 2023, Kaia Healthcare Software Inc. (Germany) Kaia Back Pain got permanently listed on the DiGA platform, making it free for consumers with statutory health insurance.
Digital Therapeutics Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
198 |
|
Format |
|
|
Forecast Period |
2024–2031 |
|
Base Year |
2023 |
|
CAGR (Value) |
31.5% |
|
Market Size (Value) |
USD 56.34 Billion by 2031 |
|
Segments Covered |
By Type
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa |
|
Key Companies |
Noom, Inc. (U.S.), 2Morrow Inc. (U.S.), GAIA AG (Germany), ResMed Inc. (U.S.), Canary Health (U.S.), Welldoc, Inc. (U.S.), DarioHealth Corp. (U.S.), Akili, Inc. (U.S.), Biofourmis Inc. (U.S.), Big Health (U.S.), Teladoc Health, Inc. (U.S.), Limbix Health, Inc. (U.S.), Kaia Health Software Inc. (Germany), Glooko, Inc. (U.S.), and Virta Health Corp. (U.S.). |
Key questions answered in the report:
The global digital therapeutics market size was valued at $ 6.46 billion in 2023.
The market is projected to grow from $ 8.26 billion in 2024 to $56.34 billion by 2031.
The digital therapeutics market analysis indicates significant growth, reaching $56.34 billion by 2031 at a compound annual growth rate (CAGR) of 31.5% from 2024 to 2031.
The key players operating in the global digital therapeutics market are Noom, Inc. (U.S.), 2Morrow Inc. (U.S.), GAIA AG (Germany), ResMed Inc. (U.S.), Canary Health (U.S.), Welldoc, Inc. (U.S.), DarioHealth Corp. (U.S.), Akili, Inc. (U.S.), Biofourmis Inc. (U.S.), Big Health (U.S.), Teladoc Health, Inc. (U.S.), Limbix Health, Inc. (U.S.), Kaia Health Software Inc. (Germany), Glooko, Inc. (U.S.), and Virta Health Corp. (U.S.).
A prominent market trend in digital therapeutics is the integration of AI in digital therapeutics.
By type, the disease management and treatment dtx segment is forecasted to hold the largest market share.
By application, the mental health segment is poised to record the dominant position in the market.
By end user, the providers segment is expected to dominate the market.
By geography, the North America segment is slated to register the largest market share
By region, North America will hold the largest digital therapeutics market Share in 2024. However, the Asia-Pacific region is expected to witness the fastest growth, driven by increasing approvals for digital therapeutics applications and supportive government initiatives for the adoption of digital health.
The shortage of healthcare professionals drives the growth of this market, the need to lower the cost of healthcare, the growing number of chronic diseases, and the rising consumer inclination towards mobile applications for digital health management.
1. Market Definition & Scope
1.1. Market Definition
1.2. Market Coverage
1.3. Market Ecosystem
1.4. Currency and Limitations
1.5. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
3.1. Overview
3.2. Segmental Analysis
3.2.1. Digital Therapeutics Market Analysis, by Type
3.2.2. Digital Therapeutics Market Analysis, by Application
3.2.3. Digital Therapeutics Market Analysis, by End User
3.3. Regional Analysis
3.4. Key Players & Competitive Scenario
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Increasing Focus on Preventive Healthcare and Self-testing is Driving the Market
4.2.2. Data Privacy Concerns Associated with Digital Therapeutics Applications are Restraining Market Growth
4.2.3. Emerging Economies and Growing Product Pipeline Providing Opportunities for Market Growth
4.2.4. Lengthy and Tedious Regulatory Approval Process Is Posing a Challenge to the Market’s Growth
4.2.5. Macroindicators
4.3. Trends
4.3.1. Partnership of Digital Therapeutics Companies with Pharmaceutical Companies
4.3.2. Integration of Artificial Intelligence (AI) in Digital Therapeutics
4.4. Regulatory and Reimbursement Approval Pathway Overview
4.4.1. U.S.
4.4.2. Germany
4.4.3. France
4.4.4. Belgium
4.4.5. U.K.
4.4.6. China
4.4.7. Japan
4.4.8. South Korea
4.5. Case Study
4.5.1. Connected Inhalers to Reduce Asthma Symptoms (Propeller Health)
4.5.2. Sharp Rees-Stealy Medical Group (U.S.) Improves Outcomes with Diabetes Management Program
4.5.3. Improvement in Self-management of Diseases with Digital Health Solutions
4.6. Pipeline Analysis
4.7. Investment & Funding Scenario
5. Digital Therapeutics Market Assessment—by Type
5.1. Overview
5.2. Disease Management and Treatment DTx
5.3. Disease Prevention DTx
6. Digital Therapeutics Market Assessment—by Application
6.1. Overview
6.2. Mental Health
6.3. Diabetes
6.4. Cardiovascular Diseases
6.5. Gastrointestinal Disorders
6.6. Neurology
6.7. Rehabilitation & Patient Care
6.8. Respiratory Disorders
6.9. Oncology
6.10. Addiction Management
6.11. Sleep Disorders
6.12. Smoking Cessation
6.13. Other Applications
7. Digital Therapeutics Market Assessment—by End Users
7.1. Overview
7.2. Providers
7.3. Individual Consumers
7.4. Employers
7.5. Payers
7.6. Other End Users
8. Digital Therapeutics Market Assessment–by Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Switzerland
8.3.7. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America (RoLATAM)
8.6. Middle East & Africa
9. Competitive Landscape
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Contemporary Stalwarts
9.5. Market Ranking Analysis, by the Key Players, 2023
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
10.1. ResMed Inc.
10.2. Teladoc Health, Inc.
10.3. Noom, Inc.
10.4. DarioHealth Corp.
10.5. GAIA AG
10.6. Biofourmis Inc.
10.7. Virta Health Corp.
10.8. Welldoc, Inc.
10.9. Glooko, Inc.
10.10. 2Morrow Inc.
10.11. Canary Health
10.12. BigHealth
10.13. Akili, Inc.
10.14. Limbix Health, Inc.
10.15. Kaia Healthcare Software Inc.
10.16. Popular Mentions
(Note: SWOT Analysis will be provided for the Top 5 Companies)
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1. Key Differences Between Digital Health, Digital Medicine, And Digital Therapeutics
Table 2. Market Authorizations of Digital Therapeutics
Table 3. Global Digital Therapeutics Market, by Type, 2022-2031 (USD Million)
Table 4. Global Digital Therapeutics Market for Disease Management and Treatment, by Country/Region, 2022–2031 (USD Million)
Table 5. Global Digital Therapeutics Market for Disease Prevention, by Country/Region, 2022–2031 (USD Million)
Table 6. Global Digital Therapeutics Market, by Applications, 2022-2031 (USD Million)
Table 7. Global Digital Therapeutics Market for Mental Health, by Country/Region, 2022–2031 (USD Million)
Table 8. Global Digital Therapeutics Market for Diabetes, by Country/Region, 2022–2031 (USD Million)
Table 9. Global Digital Therapeutics Market for Cardiovascular Diseases, by Country/Region, 2022–2031 (USD Million)
Table 10. Global Digital Therapeutics Market for Gastrointestinal Disorders, by Country/Region, 2022–2031 (USD Million)
Table 11. Global Digital Therapeutics Market for Neurology, by Country/Region, 2022–2031 (USD Million)
Table 12. Global Digital Therapeutics Market for Rehabilitation and Patient Care, by Country/Region, 2022–2031 (USD Million)
Table 13. Global Digital Therapeutics Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 14. Global Digital Therapeutics Market for Respiratory Disorders, by Country/Region, 2022–2031 (USD Million)
Table 15. Global Digital Therapeutics Market for Addiction Management, by Country/Region, 2022–2031 (USD Million)
Table 16. Global Digital Therapeutics Market for Sleep Disorder, by Country/Region, 2022–2031 (USD Million)
Table 17. Global Digital Therapeutics Market for Smoking Cessation, by Country/Region, 2022–2031 (USD Million)
Table 18. Global Digital Therapeutics Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 19. Global Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 20. Global Digital Therapeutics Market for Providers, by Country/Region, 2022–2031 (USD Million)
Table 21. Global Digital Therapeutics Market for Individual Consumers, by Country/Region, 2022–2031 (USD Million)
Table 22. Global Digital Therapeutics Market for Employers, by Country/Region, 2022–2031 (USD Million)
Table 23. Global Digital Therapeutics Market for Payers, by Country/Region, 2022–2031 (USD Million)
Table 24. Global Digital Therapeutics Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 25. Digital Therapeutics Market, by Country/Region, 2022–2031 (USD Million)
Table 26. North America: Digital Therapeutics Market, by Country/Region, 2022–2031 (USD Million)
Table 27. North America: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 28. North America: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 29. North America: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 30. U.S.: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 31. U.S.: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 32. U.S.: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 33. Canada: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 34. Canada: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 35. Canada: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 36. Europe: Digital Therapeutics Market, by Country/Region, 2022–2031 (USD Million)
Table 37. Europe: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 38. Europe: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 39. Europe: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 40. Germany: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 41. Germany: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 42. Germany: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 43. U.K.: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 44. U.K.: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 45. U.K.: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 46. France: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 47. France: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 48. France: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 49. Italy: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 50. Italy: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 51. Italy: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 52. Spain: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 53. Spain: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 54. Spain: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 55. Switzerland: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 56. Switzerland: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 57. Switzerland: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 58. Rest of Europe: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 59. Rest of Europe: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 60. Rest of Europe: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 61. Asia-Pacific: Digital Therapeutics Market, by Country/Region, 2022–2031 (USD Million)
Table 62. Asia-Pacific: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 63. Asia-Pacific: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 64. Asia-Pacific: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 65. China: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 66. China: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 67. China: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 68. Japan: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 69. Japan: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 70. Japan: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 71. India: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 72. India: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 73. India: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 74. Australia: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 75. Australia: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 76. Australia: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 77. Rest of Asia-Pacific: Digital Therapeutics Market, By Type, 2022–2031 (USD Million)
Table 78. Rest of Asia-Pacific: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 79. Rest of Asia-Pacific: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 80. Latin America: Digital Therapeutics Market, by Country/Region, 2022–2031 (USD Million)
Table 81. Latin America: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 82. Latin America: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 83. Latin America: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 84. Brazil: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 85. Brazil: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 86. Brazil: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 87. Mexico: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 88. Mexico: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 89. Mexico: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 90. People (20-79 Y) With Diabetes in Argentina, Colombia, and Chile (in Thousands)
Table 91. Rest of Latin America: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 92. Rest of Latin America: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 93. Rest of Latin America: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 94. Middle East & Africa: Digital Therapeutics Market, by Type, 2022–2031 (USD Million)
Table 95. Middle East & Africa: Digital Therapeutics Market, by Application, 2022–2031 (USD Million)
Table 96. Middle East & Africa: Digital Therapeutics Market, by End User, 2022–2031 (USD Million)
Table 97. Recent Developments, by Company, 2021–2024
List of Figures
Figure 1. Key Stakeholders
Figure 2. Research Process
Figure 3. Secondary Sources Referenced for this Study
Figure 4. Primary Research Techniques
Figure 5. Key Executives Interviewed
Figure 6. Breakdown of Primary Interviews (Supply-Side & Demand Side)
Figure 7. Market Sizing and Growth Forecast Approach
Figure 8. Global Digital Therapeutics Market Size, by Type, 2024 Vs. 2031 (USD Million)
Figure 9. Global Digital Therapeutics Market Size, by Application, 2024 Vs. 2031 (USD Million)
Figure 10. Global Digital Therapeutics Market Size, by End User, 2024 Vs. 2031 (USD Million)
Figure 11. Global Digital Therapeutics Market, by Geography
Figure 12. Global Digital Therapeutics Market: Impact Analysis
Figure 13. Germany: Reimbursement Approval Pathway
Figure 14. Global Digital Therapeutics Market, by Type, 2024 Vs. 2031 (USD Million))
Figure 15. Global Digital Therapeutics Market, by Applications, 2024 Vs. 2031 (USD Million)
Figure 16. Diabetes Patients, by Region 2021 Vs. 2030 Vs. 2045 (Million)
Figure 17. Drug Consumption Among the Population in 2020 (Million People)
Figure 18. Prevalence of Tobacco Use (% Of Adults) in 2020
Figure 19. Global Digital Therapeutics Market Size, by End User, 2024 Vs. 2031 (USD Million)
Figure 20. Digital Therapeutics Market, by Region, 2024 Vs. 2031 (USD Million)
Figure 21. North America: Digital Therapeutics Market Snapshot
Figure 22. U.S.: Number of People with Chronic Diseases, 2005-2030 (In Millions)
Figure 23. Europe: Digital Therapeutics Market Snapshot
Figure 24. Asia-Pacific: Digital Therapeutics Market Snapshot
Figure 25. Japan: Growth in Aging Population 2015-2023 (Million)
Figure 26. RoAPAC: Growth in Aging Population 2015 Vs. 2017 Vs. 2023 (Million)
Figure 27. Latin America: Digital Therapeutics Market Snapshot
Figure 28. Growth in the Elderly Population 2023 Vs. 2017 Vs. 2015
Figure 29. Key Growth Strategies Adopted by Leading Players, 2021–2024
Figure 30. Digital Therapeutics Market: Competitive Benchmarking (Based on Type)
Figure 31. Competitive Benchmarking for DTx: Based on DTx Capabilities and Therapeutic Area
Figure 32. Competitive Dashboard: Digital Therapeutics Market
Figure 33. Company Ranking: Digital Therapeutics Market (2023)
Figure 34. Resmed Inc.: Financial Snapshot (2023)
Figure 35. Teladoc Health, Inc.: Financial Overview (2023)
Figure 36. Dariohealth Corp.: Financial Snapshot (2023)
Figure 37. Akili, Inc.: Financial Snapshot (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Digital Biomanufacturing Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Sep-2024
Digital X-ray Systems Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jul-2024
Digital Health Market - Global Opportunity Analysis and Industry Forecasts (2024-2031)
Published Date: May-2024
